Aerie Pharmaceuticals reported $36.13M in Sales Revenues for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Aerie Pharmaceuticals AERI:US USD 36.13M 2.82M
Alimera Sciences ALIM:US USD 13.6M 1.01M
Amarin AMRN:US USD 89.88M 4.56M
Bluebird Bio BLUE:US USD 71K 1.45M
Cara Therapeutics CARA:US USD 10.81M 12.19M
Coherus Biosciences CHRS:US USD 45.42M 14.73M
Endo International Ordinary Shares ENDP:US USD 541.69M 27.42M
Horizon Pharma HZNP:US USD 925.36M 48.95M
Insmed INSM:US USD 67.73M 2.51M
Merk MRK:US USD 14.96B 366M
Mirati Therapeutics MRTX:US USD 5.43M 69K
Novartis NOVN:VX USD 12.84B 243M
Pacira Pharmaceuticals PCRX:US USD 167.47M 1.94M
Regeneron Pharmaceuticals REGN:US USD 2.94B 79M
Revance Therapeutics RVNC:US USD 29.01M 647K
Supernus Pharmaceuticals SUPN:US USD 177.35M 7.3M
Teva Pharmaceutical Industries TEVA:US USD 3.6B 191M
Valeant Pharmaceuticals VRX:CN USD 2.05B 79M
Zoetis ZTS:US USD 2B 50M